Regencell Bioscience Company Insiders
| RGC Stock | USD 5.10 0.60 10.53% |
Regencell Bioscience employs about 12 people. The company is managed by 33 executives with a total tenure of roughly 338 years, averaging almost 10.0 years of service per executive, having 0.36 employees per reported executive. Evaluation of Regencell Bioscience's management performance can provide insight into the firm performance.
| Amy Miles CEO Chairperson and CEO |
| Peter Bala CEO President CEO, Director |
Regencell |
Regencell Bioscience's latest congressional trading
Congressional trading in companies like Regencell Bioscience, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Regencell Bioscience by those in governmental positions are based on the same information available to the general public.
| 2017-12-08 | Senator Michael F. Bennet | Acquired $500,001 - $1,000,000 | Verify |
Regencell Bioscience Management Team Effectiveness
The company has Return on Asset of (0.2559) % which means that on every $100 spent on assets, it lost $0.2559. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4171) %, meaning that it generated no profit with money invested by stockholders. Regencell Bioscience's management efficiency ratios could be used to measure how well Regencell Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. At present, Regencell Bioscience's Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.04, whereas Return On Equity is forecasted to decline to (0.14). At present, Regencell Bioscience's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Return On Tangible Assets is expected to grow to 0.05, whereas Total Assets are forecasted to decline to about 10.8 M.As of April 25, 2024, Common Stock Shares Outstanding is expected to decline to about 11.1 M. The current year's Net Loss is expected to grow to about (6.4 M)
Regencell Bioscience Workforce Comparison
Regencell Bioscience Holdings is rated below average in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 14,894. Regencell Bioscience adds roughly 12.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Regencell Bioscience Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regencell Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regencell Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Regencell Bioscience insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Amy Miles over a month ago Disposition of 33006 shares by Amy Miles of Regencell Bioscience at 21.58 subject to Rule 16b-3 | ||
Peter Brandow over a month ago Disposition of 1265 shares by Peter Brandow of Regencell Bioscience at 22.87 subject to Rule 16b-3 |
Regencell Bioscience Notable Stakeholders
A Regencell Bioscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Regencell Bioscience often face trade-offs trying to please all of them. Regencell Bioscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Regencell Bioscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
About Regencell Bioscience Management Performance
The success or failure of an entity such as Regencell Bioscience often depends on how effective the management is. Regencell Bioscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Regencell management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Regencell management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.05 | 0.05 | |
| Return On Capital Employed | 0.12 | 0.12 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | (0.13) | (0.14) |
The data published in Regencell Bioscience's official financial statements usually reflect Regencell Bioscience's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Regencell Bioscience. For example, before you start analyzing numbers published by Regencell accountants, it's critical to develop an understanding of what Regencell Bioscience's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Regencell Bioscience's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Regencell Bioscience's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Regencell Bioscience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Regencell Bioscience Holdings. Please utilize our Beneish M Score to check the likelihood of Regencell Bioscience's management manipulating its earnings.
Regencell Bioscience Workforce Analysis
Traditionally, organizations such as Regencell Bioscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Regencell Bioscience within its industry.Regencell Bioscience Manpower Efficiency
Return on Regencell Bioscience Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 505.2K | |
| Net Loss Per Executive | 183.7K | |
| Working Capital Per Employee | 917.9K | |
| Working Capital Per Executive | 333.8K |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Return On Assets (0.26) | Return On Equity (0.42) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.